From: Classification of ductal carcinoma in situ by gene expression profiling
In situ samples | Invasive samples | ||
---|---|---|---|
Differentiation | Number (percentage) | Histological grade | Number (percentage) |
Well | 6 (15%) | 1 | 5 (12.5%) |
Intermediately | 18 (45%) | 2 | 11 (27.5%) |
Poorly | 14 (35%) | 3 | 24 (60%) |
Good/poor component | 1 (2.5%) | Â | Â |
LCIS | 1 (2.5%) | Â | Â |
IHC | Â | IHC | Â |
ER-positive | 28 (70%)a | ER-positive | 22 (55%)c |
PR-positive | 24 (60%)a | PR-positive | 19 (47.5%)d |
Her2/neu-positive (3+) | 12 (30%)b | Her2/neu-positive (3+) | 4 (10%)d |
p53-positive | 11 (27.5%)b | p53-positive | 9 (22.5%)d |
Tumour detection | Â | Â | Â |
Palpation | 17 (42.5%) | Â | Â |
Microcalcifications | 18 (45%) | Â | Â |
Others | 5 (12.5%) | Â | Â |
Tumour diameter (mm) | Â | Â | Â |
Range | 10 to 80 | Â | Â |
Median | 45 | Â | Â |
Average | 42.8 | Â | Â |
Treatment | Â | Â | Â |
Mastectomy | 24 (60%) | Â | Â |
Breast conserving treatment | 6 (15%) | Â | Â |
Local excision followed by mastectomy | 10 (25%) | Â | Â |